6,172 results on '"Pseudomonas aeruginosa Infections"'
Search Results
2. Integrated Biofilm Dispersion and Virulence Responsiveness for Targeted Treatment of Pseudomonas aeruginosa Infection in Lungs.
- Author
-
Ivanova, Kristina, Ramon, Eva, Wnorowska, Urszula, Todorova, Katerina, Ivanova, Aleksandra, Bastos‐Arrieta, Julio, Puertas‐Segura, Antonio, Deptula, Piotr, Damyanova, Tsvetozara, Paunova‐Krasteva, Tsvetelina, Bucki, Robert, Ivanov, Ivan, and Tzanov, Tzanko
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *DRUG accessibility , *DRUG bioavailability , *CYSTIC fibrosis , *STRAINS & stresses (Mechanics) - Abstract
The self‐organization of microbes into biofilms provides multiple benefits including tolerance to mechanical stress and resistance to immune defences and antibiotics. Coupled to a compromised mucociliary function, these traits have dire consequences in cystic fibrosis patients – persistent infections are the main reason for morbidity and mortality. Thereby, disease progression is associated with universal colonization by
Pseudomonas aeruginosa , which selects for a slimy phenotype to adapt to the lung microenvironment. Recognizing this, drug‐delivery vehicles that break down the mucoid extracellular matrix made of alginate are designed to enable better penetration and biofilm dispersion. In parallel, a protective layer responds to the proteolytic activity of the pathogen and thus controls drug availability. To realize this architecture, silica nanoparticles are loaded with imipenem, and then coated with elastin and alginate lyase in a layer‐by‐layer fashion using ultrasound. The nanoscale formulations eradicate up to 80% of the total biomass and reduce the bacterial viability in biofilms by 3 logs, considerably outperforming the bulk antibiotic in vitro, whereby the effects are correlated to changes in the viscoelasticity. Furthermore, the stimuli‐responsive nanocarriers are safe and effective in animal models ofP. aeruginosa infection, presenting a considerable therapeutic promise in the challenging context of lung diseases. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. Pseudomonas aeruginosa Infection and Inflammation in Cystic Fibrosis: A Pilot Study With Lung Explants and a Novel Histopathology Scoring System.
- Author
-
Malhotra, Sankalp, Yang, Ching, Nicholson, Kerri L., Wozniak, Daniel J., and Hayes Jr, Don
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *CYSTIC fibrosis , *LUNG diseases , *PSEUDOMONAS aeruginosa , *LUNGS - Abstract
Purpose: Pseudomonas aeruginosa is the predominant bacterial pathogen colonizing the cystic fibrosis (CF) lung. Mixed populations of nonmucoid and mucoid variants of P. aeruginosa have been isolated from the CF airway. While the association between mucoid variants and pulmonary function decline is well-established, their impact on inflammation and tissue damage in advanced CF lung disease remains unclear. Methods: This pilot study utilized 1 non-CF and 3 CF lung explants to examine lobar distribution, inflammation, and histopathology related to nonmucoid and mucoid P. aeruginosa infection. To study tissue damage, we developed a novel lung histopathology scoring system, the first applied to human CF lung biopsies, which is comprised of five indicators: bronchiolar epithelial infiltrate, luminal inflammation, peribronchial/bronchiolar infiltrate, peribronchiolar fibrosis, and alveolar involvement. Results: Mucoid P. aeruginosa variants were distributed throughout the CF lung but associated with greater concentrations of proinflammatory cytokines, IL-1β, TNF-α, IL-6, IL-8, and IFN-γ, and one anti-inflammatory cytokine, IL-10, compared to nonmucoid variants. CF lung explants exhibited higher histopathology scores compared to a non-CF lung control. In mixed-variant infection, nonmucoid constituents associated with increased bronchiolar epithelial infiltration, one indicator of histopathology. Conclusion: This pilot study suggests ongoing interplay between host and bacterial elements in late-stage CF pulmonary disease. Mucoid P. aeruginosa infection correlates with inflammation regardless of lung lobe, whereas nonmucoid P. aeruginosa is associated with increased inflammatory cell infiltration. The development of a novel lung histopathology scoring system lays the groundwork for future large-cohort investigations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Novel β-lactam-β-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort study.
- Author
-
Almangour, Thamer A., Ghonem, Leen, Alassiri, Dareen, Aljurbua, Alanoud, Al Musawa, Mohammed, Alharbi, Aminah, Almuhisen, Sara, Alghaith, Jeelan, Damfu, Nader, Aljefri, Doaa, Alfahad, Wafa, Alrasheed, Marwan, Khormi, Yaqoub, and Almohaizeie, Abdullah
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *ACUTE kidney failure , *LOGISTIC regression analysis , *SEPTIC shock , *INTENSIVE care units - Abstract
Data comparing the clinical outcomes of novel β-lactam-β-lactamase inhibitors given in combination versus monotherapy for the treatment of multidrug-resistant (MDR) P. aeruginosa infections are lacking. This retrospective cohort study included patients who received novel β-lactam–β-lactamase inhibitors as monotherapy or in combination for the treatment of MDR P. aeruginosa infections. The study was conducted between 2017 and 2022 in 6 tertiary care hospitals in Saudi Arabia. Overall in-hospital mortality, 30-day mortality, clinical cure, and acute kidney injury (AKI) were compared between recipients of monotherapy versus combination using multivariate logistic regression analysis. 118 patients and 82 patients were included in monotherapy and combination therapy arms, respectively. The cohort represented an ill population with 56% in the intensive care unit and 37% in septic shock. A total of 19% of patients presented with bacteremia. Compared to monotherapy, combination therapy did not significantly differ in clinical cure (57% vs. 68%; P = 0.313; OR, 0.63; 95% CI, 0.36–1.14) in-hospital mortality (45% vs. 37%; P = 0.267; OR, 1.38; 95% CI, 0.78–2.45), or 30-day mortality (27% vs. 24%; P = 0.619; OR, 1.18; 95% CI, 0.62–1.25). However, AKI (32% vs. 12%; P = 0.0006; OR, 3.45; 95% CI, 1.67–7.13) was significantly more common in patients who received combination therapy. Novel β-lactam–β-lactamase inhibitors when used in combination with other antibiotics did not add clinical benefit compared to their use as monotherapy in the treatment of MDR P. aeruginosa infections. A Combination regimen was associated with an increased risk of nephrotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.
- Author
-
Haworth, Charles S, Shteinberg, Michal, Winthrop, Kevin, Barker, Alan, Blasi, Francesco, Dimakou, Katerina, Morgan, Lucy C, O'Donnell, Anne E, Ringshausen, Felix C, Sibila, Oriol, Thomson, Rachel M, Carroll, Kevin J, Pontenani, Federica, Castellani, Paola, and Chalmers, James D
- Subjects
PSEUDOMONAS aeruginosa infections ,CLINICAL trials ,END of treatment ,TELEPHONE calls ,LUNG infections - Abstract
Chronic lung infection with Pseudomonas aeruginosa is associated with increased exacerbations and mortality in people with bronchiectasis. The PROMIS-I and PROMIS-II trials investigated the efficacy and safety of 12-months of inhaled colistimethate sodium delivered via the I-neb. Two randomised, double-blind, placebo-controlled trials of twice per day colistimethate sodium versus placebo were conducted in patients with bronchiectasis with P aeruginosa and a history of at least two exacerbations requiring oral antibiotics or one requiring intravenous antibiotics in the previous year in hospitals in Argentina, Australia, Belgium, Canada, France, Germany, Greece, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Spain, Switzerland, the UK, and the USA. Randomisation was conducted through an interactive web response system and stratified by site and long term use of macrolides. Masking was achieved by providing colistimethate sodium and placebo in identical vials. After random assignment, study visits were scheduled for 1, 3, 6, 9, and 12 months (the end of the treatment period); and telephone calls were scheduled for 7 days after random assignment and 2 weeks after the end of treatment. The primary endpoint was the mean annual exacerbation rate. These trials are registered with EudraCT: number 2015–002743–33 (for PROMIS-I) and 2016–004558–13 (for PROMIS-II), and are now completed. 377 patients were randomly assigned in PROMIS-I (177 to colistimethate sodium and 200 to placebo; in the modified intention-to-treat population, 176 were in the colistimethate sodium group and 197 were in the placebo group) between June 6, 2017, and April 8, 2020. The annual exacerbation rate was 0·58 in the colistimethate sodium group versus 0·95 in the placebo group (rate ratio 0·61; 95% CI 0·46–0·82; p=0·0010). 287 patients were randomly assigned in PROMIS-II (152 were assigned to colistimethate sodium and 135 were assigned to placebo, in the modified intention-to-treat population), between Feb 12, 2018, and Oct 22, 2021. PROMIS-II was then prematurely terminated due to the effect of the COVID-19 pandemic. No significant difference was observed in the annual exacerbation rate between the colistimethate sodium and placebo groups (0·89 vs 0·89; rate ratio 1·00; 95% CI 0·75–1·35; p=0·98). No major safety issues were identified. The overall frequency of adverse events was 142 (81%) patients in the colistimethate sodium group versus 159 (81%) patients in the placebo group in PROMIS-I, and 123 (81%) patients versus 104 (77%) patients in PROMIS-II. There were no deaths related to study treatment. The data from PROMIS-I suggest a clinically important benefit of colistimethate sodium delivered via the I-neb adaptive aerosol delivery system in patients with bronchiectasis and P aeruginosa infection. These results were not replicated in PROMIS-II, which was affected by the COVID-19 pandemic and prematurely terminated. Zambon. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients.
- Author
-
Thornton, Christina S., Waddell, Barbara J., Congly, Stephen E., Svishchuk, Julianna, Somayaji, Ranjani, Fatovich, Linda, Isaac, Debra, Doucette, Karen, Fonseca, Kevin, Drews, Steven J., Borlang, Jamie, Osiowy, Carla, and Parkins, Michael D.
- Subjects
HEPATITIS E virus ,HEPATITIS A virus ,HEPATITIS associated antigen ,MEDICAL societies ,PSEUDOMONAS aeruginosa infections ,CIRCOVIRUS diseases ,EXOCRINE pancreatic insufficiency - Published
- 2024
- Full Text
- View/download PDF
7. Role of factor H-related protein 3 in Pseudomonas aeruginosa bloodstream infections.
- Author
-
González-Alsina, Alex, Martín-Merinero, Héctor, Mateu-Borrás, Margalida, Verd, María, Doménech-Sánchez, Antonio, Goldberg, Joanna B., Rodríguez de Córdoba, Santiago, and Albertí, Sebastián
- Subjects
PSEUDOMONAS aeruginosa infections ,COMPLEMENT factor H ,BLOOD proteins ,BACTERIAL cell surfaces ,COMPLEMENT activation - Abstract
Pseudomonas aeruginosa is a leading cause of nosocomial bloodstream infections. The outcome of these infections depends on the virulence of the microorganism as well as host-related conditions and factors. The complement system plays a crucial role in defense against bloodstream infections. P. aeruginosa counteracts complement attack by recruiting Factor H (FH) that inhibits complement amplification on the bacterial surface. Factor H-related proteins (FHRs) are a group of plasma proteins evolutionarily related to FH that have been postulated to interfere this bacterial evasion mechanism. In this study, we demonstrate that FHR-3 competes with purified FH for binding to P. aeruginosa and identify EF-Tu as a common bacterial target for both complement regulator factors. Importantly, elevated levels of FHR-3 in human serum promote complement activation, leading to increased opsonization and killing of P. aeruginosa. Conversely, physiological concentrations of FHR-3 have no significant effect. Our findings suggest that FHR-3 may serve as a protective host factor against P. aeruginosa infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis.
- Author
-
Ledger, Emma L, Smith, Daniel J, Teh, Jing Jie, Wood, Michelle E, Whibley, Page E, Morrison, Mark, Goldberg, Joanna B, Reid, David W, and Wells, Timothy J
- Subjects
- *
CYSTIC fibrosis transmembrane conductance regulator , *PSEUDOMONAS aeruginosa infections , *CHLORIDE channels , *CYSTIC fibrosis , *COMPARATIVE genomics - Abstract
Background Pseudomonas aeruginosa is a multidrug-resistant pathogen causing recalcitrant pulmonary infections in people with cystic fibrosis (pwCF). Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been developed that partially correct the defective chloride channel driving disease. Despite the many clinical benefits, studies in adults have demonstrated that while P. aeruginosa sputum load decreases, chronic infection persists. Here, we investigate how P. aeruginosa in pwCF may change in the altered lung environment after CFTR modulation. Methods P. aeruginosa strains (n = 105) were isolated from the sputum of 11 chronically colonized pwCF at baseline and up to 21 months posttreatment with elexacaftor-tezacaftor-ivacaftor or tezacaftor-ivacaftor. Phenotypic characterization and comparative genomics were performed. Results Clonal lineages of P. aeruginosa persisted after therapy, with no evidence of displacement by alternative strains. We identified commonly mutated genes among patient isolates that may be positively selected for in the CFTR-modulated lung. However, classic chronic P. aeruginosa phenotypes such as mucoid morphology were sustained, and isolates remained just as resistant to clinically relevant antibiotics. Conclusions Despite the clinical benefits of CFTR modulators, clonal lineages of P. aeruginosa persist that may prove just as difficult to manage in the future, especially in pwCF with advanced lung disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Mucin adhesion of serial cystic fibrosis airways Pseudomonas aeruginosa isolates.
- Author
-
Herrmann, Christian, Lingner, Meike, Herrmann, Susanne, Brockhausen, Inka, and Tümmler, Burkhard
- Subjects
PSEUDOMONAS aeruginosa infections ,BACTERIAL adhesion ,CYSTIC fibrosis ,MUCINS ,PSEUDOMONAS aeruginosa - Abstract
The chronic airway infections with Pseudomonas aeruginosa are the major comorbidity in people with cystic fibrosis (CF). Within CF lungs, P. aeruginosa persists in the conducting airways together with human mucins as the most abundant structural component of its microenvironment. We investigated the adhesion of 41 serial CF airway P. aeruginosa isolates to airway mucin preparations from CF sputa. Mucins and bacteria were retrieved from five modulator-naïve patients with advanced CF lung disease. The P. aeruginosa isolates from CF airways and non-CF reference strains showed a strain-specific signature in their adhesion to ovine, porcine and bovine submaxillary mucins and CF airway mucins ranging from no or low to moderate and strong binding. Serial CF clonal isolates and colony morphotypes from the same sputum sample were as heterogeneous in their affinity to mucin as representatives of other clones thus making 'mucin binding' one of the most variable intraclonal phenotypic traits of P. aeruginosa known to date. Most P. aeruginosa CF airway isolates did not adhere more strongly to CF airway mucins than to plastic surfaces. The strong binders, however, exhibited a strain-specific affinity gradient to O-glycans, CF airway and mammalian submaxillary mucins. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. cUMP elicits interendothelial gap formation during Pseudomonas aeruginosa infection.
- Author
-
deWeever, Althea, Paudel, Sunita S., Zhou, Chun, Francis, C. Michael, Tambe, Dhananjay T., Frank, Dara W., Balczon, Ron, and Stevens, Troy
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *CYCLIC nucleotides , *PYRIMIDINE nucleotides , *PULMONARY edema , *LUNG infections - Abstract
Pseudomonas aeruginosa utilizes a type 3 secretion system to intoxicate host cells with the nucleotidyl cyclase ExoY. After activation by its host cell cofactor, filamentous actin, ExoY produces purine and pyrimidine cyclic nucleotides, including cAMP, cGMP, and cUMP. ExoY-generated cyclic nucleotides promote interendothelial gap formation, impair motility, and arrest cell growth. The disruptive activities of cAMP and cGMP during the P. aeruginosa infection are established; however, little is known about the function of cUMP. Here, we tested the hypothesis that cUMP contributes to endothelial cell barrier disruption during P. aeruginosa infection. Using a membrane permeable cUMP analog, cUMP-AM, we revealed that during infection with catalytically inactive ExoY, cUMP promotes interendothelial gap formation in cultured pulmonary microvascular endothelial cells (PMVECs) and contributes to increased filtration coefficient in the isolated perfused lung. These findings indicate that cUMP contributes to endothelial permeability during P. aeruginosa lung infection. NEW & NOTEWORTHY: During pneumonia, bacteria utilize a virulence arsenal to communicate with host cells. The Pseudomonas aeruginosa T3SS directly introduces virulence molecules into the host cell cytoplasm. These molecules are enzymes that trigger interkingdom communication. One of the exoenzymes is a nucleotidyl cyclase that produces noncanonical cyclic nucleotides like cUMP. Little is known about how cUMP acts in the cell. Here we found that cUMP instigates pulmonary edema during Pseudomonas aeruginosa infection of the lung. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Outer membrane vesicles from X‐ray‐irradiated Pseudomonas aeruginosa alleviate lung injury caused by P. aeruginosa infection‐mediated sepsis.
- Author
-
Bi, Hongxia, Qin, Jiayuan, Huang, Jiaqi, Zhong, Cejun, and Liu, Yanbin
- Subjects
- *
EXTRACELLULAR vesicles , *PSEUDOMONAS aeruginosa infections , *BACTERIAL colonies , *THERAPEUTICS , *PERITONEUM - Abstract
Pseudomonas aeruginosa infection causes pneumonia and sepsis. Previous research found that X‐ray radiation can induce P. aeruginosa to release outer membrane vesicles (OMVs) of relatively consistent sizes. This study found that OMVs derived from X‐ray‐irradiated P. aeruginosa can significantly inhibit lung leakage, inflammatory cell infiltrating into lung, and the production of pro‐inflammatory cytokines, IL‐1β and TNFα caused by P. aeruginosa infection under preventive and therapeutic administration conditions. Under the same conditions, OMVs also significantly alleviated pathological characteristics of lung injury, including pulmonary edema, pulmonary hemorrhage, and alveolar wall thickening. OMVs also significantly reduced bacterial burdens in peritoneal cavity, accompanied by a reduction in the number of viable bacteria capable of forming bacterial colonies. Pretreating macrophages and neutrophils with OMVs enhances their bactericidal ability. When bacteria were cocultured with treated cells, the number of viable bacteria capable of forming bacterial colonies was significantly reduced. OMVs themselves have not been shown to cause any lung injury or affect bacterial viability. Therefore, OMVs derived from X‐ray‐irradiated P. aeruginosa may not only be applied in prevention and treatment of diseases associated with P. aeruginosa infection, but also served as an excellent vaccine development platform. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Bacteriophage Therapy on an In Vitro Wound Model and Synergistic Effects in Combination with Beta-Lactam Antibiotics.
- Author
-
Santamaría-Corral, Guillermo, Aguilera-Correa, John Jairo, Esteban, Jaime, and García-Quintanilla, Meritxell
- Subjects
PSEUDOMONAS aeruginosa infections ,BETA lactam antibiotics ,MULTIDRUG resistance ,BACTERIAL diseases ,BACTERIAL growth ,WOUND infections - Abstract
One of the primary opportunistic pathogens that can cause a wide range of diseases is Pseudomonas aeruginosa. This microorganism can become resistant to practically every antibacterial currently in use, including beta-lactam antibiotics. Its ability to proliferate as biofilm has been linked to, among other things, the failure of antimicrobial therapies. Due to a variety of virulence factors and host immune system modifications, P. aeruginosa is one of the most significant and common bacteria that colonize wounds and burns. A novel therapeutic option for treating these multidrug-resistant (MDR) bacterial infections is the combination of antibiotics and bacteriophages. This approach has been linked to improved biofilm penetration, a decreased selection of antibiotic and bacteriophage resistance, and an enhanced antibacterial impact. Combining the F1Pa bacteriophage and beta-lactam antibiotics reduced the viability of the mature biofilm of MDR P. aeruginosa strains and suppressed bacterial growth in vitro. F1Pa critically reduced the amount of biofilm that MDR P. aeruginosa clinical strains formed in the in vitro wound model. These findings highlight the bacteriophage F1Pa's therapeutic potential as a prophylactic topical treatment against MDR pseudomonal infections in wounds and burns. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Synergistic Treatment of Infected Burn Wound Utilizing Maggot Debridement and Acellular Fish Skin Grafting—A Case Report.
- Author
-
Borger, Anton, Semmler, Lorenz, Bergmann, Felix, Supper, Paul, and Radtke, Christine
- Subjects
PSEUDOMONAS aeruginosa infections ,LEG injuries ,MAGGOT therapy ,FISH skin ,CHRONIC wounds & injuries ,WOUND infections - Abstract
Here, we report about a patient with a full-thickness burn injury of the left lower extremity with approximately 8% of total BSA affected. Initial therapy consisted of necrosectomy and wound coverage with split-thickness graft. The patient developed a wound infection with Pseudomonas aeruginosa , resulting in the failure of the skin graft to achieve complete healing. The case was further complicated by the patient's concurrent presentation of anemia, characterized by a hematocrit level of 19.8% on 11th day after admission. Additionally, the patient refused acceptance of any blood transfusion, adding a significant layer of complexity to the management strategy. In summary, the patient's critical state required an immediate intervention. Due to the contraindication for a further surgical debridement and autograft, we changed the treatment strategy to a conservative approach. First, the wound was debrided employing maggot therapy 17 days after admission. Subsequently, free soft tissue coverage was accomplished using decellularized fish skin dressings on 45th day. This approach yielded satisfactory wound closure. Following an approximately 2-month hospitalization period (52nd day after admission), the patient was discharged with a stable wound condition, nearing complete healing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Antibody-Mediated Serum Resistance Protects Pseudomonas aeruginosa During Bloodstream Infections.
- Author
-
Hickson, Sarah M, Hoehensteiger, Johannes K, Mayer-Coverdale, Johanna, Torres, Von Vergel L, Feng, Wenkang, Monteith, Joshua N, Henderson, Ian R, McCarthy, Kate L, and Wells, Timothy J
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *BACTERICIDAL action , *PSEUDOMONAS aeruginosa , *BACTERIAL diseases , *IMMUNOGLOBULINS - Abstract
Background Pseudomonas aeruginosa is a frequent pathogen isolated from bacterial bloodstream infection (BSI) and is associated with high mortality. To survive in the blood, P aeruginosa must resist the bactericidal action of complement (ie, serum killing). Antibodies usually promote serum killing through the classical complement pathway; however, "cloaking antibodies" (cAbs) have been described, which paradoxically protect bacteria from serum killing. The relevance of cAbs in P aeruginosa BSI is unknown. Methods Serum and P aeruginosa were collected from a cohort of 100 patients with BSI. Isolates were tested for sensitivity to healthy control serum (HCS). cAb prevalence was determined in sera. Patient sera were mixed with HCS to determine if killing of the matched isolate was inhibited. Results Overall, 36 patients had elevated titers of cAbs, and 34 isolates were sensitive to HCS killing. Fifteen patients had cAbs and HCS-sensitive isolates; of these patients, 14 had serum that protected their matched bacteria from HCS killing. Patients with cAbs were less likely to be neutropenic or have comorbidities. Conclusions cAbs are prevalent in patients with P aeruginosa BSI and allow survival of otherwise serum-sensitive bacteria in the bloodstream. Generation of cAbs may be a risk factor for the development of BSI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Improvement of a mouse infection model to capture Pseudomonas aeruginosa chronic physiology in cystic fibrosis.
- Author
-
Duncan, Rebecca P., Moustafa, Dina A., Lewin, Gina R., Diggle, Frances L., Bomberger, Jennifer M., Whiteley, Marvin, and Goldberg, Joanna B.
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *BACTERIAL physiology , *HUMAN physiology , *CYSTIC fibrosis , *BACTERIAL genes - Abstract
Laboratory models are central to microbiology research, advancing the understanding of bacterial physiology by mimicking natural environments, from soil to the human microbiome. When studying host-bacteria interactions, animal models enable investigators to examine bacterial dynamics associated with a host, and in the case of human infections, animal models are necessary to translate basic research into clinical treatments. Efforts toward improving animal infection models are typically based on reproducing host genotypes/phenotypes and disease manifestations, leaving a gap in how well the physiology of microbes reflects their behavior in a human host. Understanding bacterial physiology is vital because it dictates host response and bacterial interactions with antimicrobials. Thus, our goal was to develop an animal model that accurately recapitulates bacterial physiology in human infection. The system we chose to model was a chronic Pseudomonas aeruginosa respiratory infection in cystic fibrosis (CF). To accomplish this goal, we leveraged a framework that we recently developed to evaluate model accuracy by calculating the percentage of bacterial genes that are expressed similarly in a model to how they are expressed in their infection environment. We combined two complementary models of P. aeruginosa infection--an in vitro synthetic CF sputum model (SCFM2) and a mouse acute pneumonia model. This combined model captured the chronic physiology of P. aeruginosa in CF better than the standard mouse infection model, showing the power of a data-driven approach to refining animal models. In addition, the results of this work challenge the assumption that a chronic infection model requires long-term colonization. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. PDIA iminosugar influence on subcutaneous Staphylococcus aureus and Pseudomonas aeruginosa infections in mice.
- Author
-
Kozień, Łucja, Policht, Aleksandra, Heczko, Piotr, Arent, Zbigniew, Bracha, Urszula, Pardyak, Laura, Pietsch-Fulbiszewska, Agnieszka, Gallienne, Estelle, Piwowar, Piotr, Okoń, Krzysztof, Tomusiak-Plebanek, Anna, and Strus, Magdalena
- Subjects
PSEUDOMONAS aeruginosa infections ,STAPHYLOCOCCUS aureus infections ,STAPHYLOCOCCAL diseases ,PSEUDOMONAS diseases ,DIABETIC foot - Abstract
Introduction: Biofilm-associated infections persist as a therapeutic challenge in contemporary medicine. The efficacy of antibiotic therapies is ineffective in numerous instances, necessitating a heightened focus on exploring novel antibiofilm medical strategies. Among these, iminosugars emerge as a distinctive class of compounds displaying promising biofilm inhibition properties. Methods: This study employs an in vivo wound infection mouse model to evaluate the effectiveness of PDIA in treating biofilm-associated skin wound infections caused by Staphylococcus aureus and Pseudomonas aeruginosa. Dermic wounds in mice were infected with biofilm-forming strains, specifically S. aureus 48 and P. aeruginosa 5, which were isolated from patients with diabetic foot, and are well-known for their strong biofilm formation. The subsequent analysis included clinical, microbiological, and histopathological parameters. Furthermore, an exploration into the susceptibility of the infectious strains to hydrogen peroxide was conducted, acknowledging its potential presence during induced inflammation in mouse dermal wounds within an in vivo model. Results: The findings revealed the efficacy of PDIA iminosugar against the S. aureus strain, evidenced by a reduction in bacterial numbers within the wound and the inflammatory focus. Discussion: This study suggests that PDIA iminosugar emerges as an active and potentially effective antibiofilm agent, positioning it as a viable treatment option for staphylococcal infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. THP-1 Macrophages Limit Neutrophil Transendothelial Migration in a Model Infection.
- Author
-
Ignes-Romeu, Aitana, Weppner, Hannah K., Kaur, Tanisha, Singh, Maya, and Hind, Laurel E.
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *NATURAL immunity , *CELL populations , *EXTRACELLULAR matrix , *NEUTROPHILS , *MICROFLUIDIC devices - Abstract
Introduction: Dysregulated neutrophil function plays a significant role in the pathology of infections, cancer, cardiovascular diseases, and autoimmune disorders. Neutrophil activity is influenced by various cell populations, including macrophages, which are crucial regulators. However, the exact role of human macrophages in controlling neutrophil function remains unclear due to a scarcity of studies utilizing human cells in physiologically relevant models. Methods: We adapted our "Infection-on-a-Chip" microfluidic device to incorporate macrophages within the collagen extracellular matrix, allowing for the study of interactions between human neutrophils and macrophages in a context that mimics in vivo conditions. The integration of THP-1 macrophages was optimized and their effect on the endothelial lumen was characterized, focusing on permeability and structural integrity. The device was then employed to examine the influence of macrophages on neutrophil response to infection with the bacterial pathogen Pseudomonas aeruginosa. Results: Integration of THP-1 macrophages into the microfluidic device was successfully optimized, showing no increase in endothelial permeability or structural damage. The presence of macrophages was found to significantly reduce neutrophil transendothelial migration in response to Pseudomonas aeruginosa infection. Conclusions: Our findings highlight the regulatory role of macrophages in modulating neutrophil responses, suggesting potential therapeutic targets to control neutrophil function in various diseases. The modified microfluidic platform offers a valuable tool for mechanistic studies into macrophage-neutrophil interactions in disease contexts. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Dry Powder Inhaler Formulation of Lactobacillus rhamnosus GG Targeting Pseudomonas aeruginosa Infection in Bronchiectasis Maintenance Therapy.
- Author
-
Tran, The-Thien, Cheow, Wean Sin, Pu, Siyu, Park, Jin-Won, and Hadinoto, Kunn
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *LACTIC acid bacteria , *LACTOBACILLUS rhamnosus , *SPRAY drying , *LUNG infections , *LUNGS - Abstract
The inhaled delivery of lactic acid bacteria (LAB) probiotics has been demonstrated to exert therapeutic benefits to the lungs due to LAB's immunomodulatory activities. The development of inhaled probiotics formulation, however, is in its nascent stage limited to nebulized LAB. We developed a dry powder inhaler (DPI) formulation of lactobacillus rhamnosus GG (LGG) intended for bronchiectasis maintenance therapy by spray freeze drying (SFD). The optimal DPI formulation (i.e., LGG: mannitol: lactose: leucine = 35: 45: 15: 5 wt.%) was determined based on the aerosolization efficiency (86% emitted dose and 26% respirable fraction) and LGG cell viability post-SFD (7 log CFU/mL per mg powder). The optimal DPI formulation was evaluated and compared to lyophilized naked LGG by its (1) adhesion capacity and cytotoxicity to human lung epithelium cells (i.e., A549 and 16HBE14o- cells) as well as its (2) effectiveness in inhibiting the growth and adhesion of Pseudomonas aeruginosa to lung cells. The optimal DPI of LGG exhibited similar non-cytotoxicity and adhesion capacity to lung cells to naked LGG. The DPI of LGG also inhibited the growth and adhesion of P. aeruginosa to the lung cells as effectively as the naked LGG. The present work established the feasibility of delivering the LAB probiotic by the DPI platform without adversely affecting LGG's anti-pseudomonal activities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. A novel antimicrobial peptide S24 combats serious wound infections caused by Pseudomonas aeruginosa and Acinetobacter baumannii.
- Author
-
Zhang, Meng-Yue, Li, Shuang, Wang, Cai-Yun, Zhang, Zi-Xuan, Han, Yu-Ling, Liu, Xin-Qi, Cheng, Juan, Zhou, Xun-Yong, and Zhang, Yi-Xuan
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *ANTIMICROBIAL peptides , *BACTERIAL diseases , *PATHOGENIC bacteria , *BACTERIAL DNA - Abstract
Objectives Pseudomonas aeruginosa and Acinetobacter baumannii are ranked as top-priority organisms by WHO. Antimicrobial peptides (AMPs) are promising antimicrobial agents that are highly effective against serious bacterial infections. Methods In our previous study, a series of α-helical AMPs were screened using a novel multiple-descriptor strategy. The current research suggested that S24 exhibited strong antimicrobial activity against major pathogenic bacteria, and displayed minimal haemolysis, good serum stability and maintained salt resistance. Results We found that S24 exerted an antimicrobial effect by destroying outer membrane permeability and producing a strong binding effect on bacterial genomic DNA that inhibits genomic DNA migration. Furthermore, S24 exerted a strong ability to promote healing in wound infected by P. aeruginosa , A. baumannii and mixed strains in a mouse model. Conclusions Overall, S24 showed good stability under physiological conditions and excellent antimicrobial activity, suggesting it may be a potential candidate for the development of serious bacterial infection treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Treatments and predictors of mortality for carbapenem-resistant gram-negative Bacilli infections in Malaysia: A retrospective cohort study
- Author
-
Abubakar, Usman, Zulkarnain, Amni Izzati, Rodriguez-Bano, Jesus, Kamarudin, Norhidayah, Elrggal, Mahmoud E, Elnaem, Mohamed Hassan, and Harun, Sabariah Noor
- Published
- 2022
21. Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience.
- Author
-
Leanza, Cristiana, Mascellino, Maria Teresa, Volpicelli, Lorenzo, Covino, Sara, Falletta, Antonio, Cancelli, Francesca, Franchi, Cristiana, Carnevalini, Martina, Mastroianni, Claudio M., and Oliva, Alessandra
- Subjects
PSEUDOMONAS aeruginosa infections ,SOFT tissue infections ,URINARY tract infections ,KLEBSIELLA pneumoniae ,TREATMENT effectiveness - Abstract
Introduction: Real-life experience with imipenem/cilastatin/relebactam (IMI/REL) for the treatment of KPC-producing Klebsiella pneumoniae complex (KPCKp) and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa (DTR-PA) infections is herein described. Methods: Adult patients with KPC-Kp or DTR-PA infections who received =48 h of IMI/REL were included. Clinical and microbiological outcomes were retrieved through the medical records. Primary outcome was clinical cure. Secondary outcomes included mortality from infection onset and adverse effects attributable to IMI/REL. Results: We included 10 patients with different infections caused by DTRPA (n = 4), KPC-Kp [n = 5, of which 3 ceftazidime/avibactam-resistant (CTV-R KPC-Kp), 2 CTV susceptible (CTV-S KPC-Kp)] or both DTR-PA/KPC-Kp (n = 1) successfully treated with IMI/REL: 3 hospital-acquired pneumonia, 1 ventilatorassociated pneumonia, 2 skin and soft tissue infections, 1 osteomyelitis, 2 bloodstream infections, 1 complicated urinary tract infection. Clinical cure was achieved in all cases. No patients died and no side effect were reported. Discussion: We reported the preliminary real-life experience on the successful and safe use of IMI/REL for the treatment of KPC-Kp or DTR-PA complicated infections, including pneumonia and bone infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Prevalence and mechanisms of aminoglycoside resistance among drug-resistant Pseudomonas aeruginosa clinical isolates in Iran.
- Author
-
Saeli, Nilofar, Jafari-Ramedani, Saghar, Ramazanzadeh, Rashid, Nazari, Maryam, Sahebkar, Amirhossein, and Khademi, Farzad
- Subjects
- *
PSEUDOMONAS aeruginosa , *PSEUDOMONAS aeruginosa infections , *GENE amplification , *POLYMERASE chain reaction , *NOSOCOMIAL infections , *PSEUDOMONAS syringae - Abstract
Background: Aminoglycosides have been a cornerstone of the treatment of nosocomial infections caused by Pseudomonas aeruginosa for over 80 years. However, escalating emergence of resistance poses a significant challenge. Therefore, this study aimed to investigate the prevailing patterns of aminoglycoside resistance among clinical isolates of P. aeruginosa in Iran; as well as the underlying resistance mechanisms observed in patients referred to Ardabil hospitals. Methods: A total of 200 isolates from five hospitals were evaluated. The resistance profiles of P. aeruginosa isolates to tobramycin, amikacin, and netilmicin were determined using the disk diffusion method. The capacity of aminoglycoside-resistant isolates to form biofilms was assessed through a phenotypic assay, and the results were confirmed using the gene amplification technique. The presence of genes associated with aminoglycoside resistance was detected using polymerase chain reaction (PCR). Quantitative reverse transcription PCR (qRT-PCR) was performed to measure the expression levels of genes encoding the MexXY-OprM efflux pump and PhoPQ two-component system (TCS). Results: The prevalence of aminoglycoside-resistant P. aeruginosa isolates was 48%, with 94.7% demonstrating multidrug resistance (MDR). All aminoglycoside-resistant P. aeruginosa strains exhibited biofilm-forming capabilities and harbored all the genes associated with biofilm production. Among the nine genes encoding 16S rRNA methylase and aminoglycoside-modifying enzymes, three genes were detected in these isolates: aac(6')-Ib (85.4%), ant(2")-Ia (18.7%), and aph(3')-VI (3.1%). Additionally, all aminoglycoside-resistant P. aeruginosa isolates carried mexY and phoP genes, although the expression levels of mexY and phoP were 75% and 87.5%, respectively. Conclusion: Given the considerably high prevalence of aminoglycoside-resistant P. aeruginosa strains, urgent measures are warranted to transition towards the use of novel aminoglycosides and to uphold vigilant surveillance of resistance patterns. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Unveiling the microevolution of antimicrobial resistance in selected Pseudomonas aeruginosa isolates from Egyptian healthcare settings: A genomic approach.
- Author
-
Salem, Salma, Abdelsalam, Nehal Adel, Shata, Ahmed H., Mouftah, Shaimaa F., Cobo-Díaz, José F., Osama, Dina, Atteya, Reham, and Elhadidy, Mohamed
- Subjects
- *
MOBILE genetic elements , *DRUG resistance in microorganisms , *PSEUDOMONAS aeruginosa , *HORIZONTAL gene transfer , *PSEUDOMONAS aeruginosa infections , *WHOLE genome sequencing , *SINGLE nucleotide polymorphisms , *PLASMIDS , *QUORUM sensing - Abstract
The incidence of Pseudomonas aeruginosa infections in healthcare environments, particularly in low-and middle-income countries, is on the rise. The purpose of this study was to provide comprehensive genomic insights into thirteen P. aeruginosa isolates obtained from Egyptian healthcare settings. Phenotypic analysis of the antimicrobial resistance profile and biofilm formation were performed using minimum inhibitory concentration and microtiter plate assay, respectively. Whole genome sequencing was employed to identify sequence typing, resistome, virulome, and mobile genetic elements. Our findings indicate that 92.3% of the isolates were classified as extensively drug-resistant, with 53.85% of these demonstrating strong biofilm production capabilities. The predominant clone observed in the study was ST773, followed by ST235, both of which were associated with the O11 serotype. Core genome multi-locus sequence typing comparison of these clones with global isolates suggested their potential global expansion and adaptation. A significant portion of the isolates harbored Col plasmids and various MGEs, all of which were linked to antimicrobial resistance genes. Single nucleotide polymorphisms in different genes were associated with the development of antimicrobial resistance in these isolates. In conclusion, this pilot study underscores the prevalence of extensively drug-resistant P. aeruginosa isolates and emphasizes the role of horizontal gene transfer facilitated by a diverse array of mobile genetic elements within various clones. Furthermore, specific insertion sequences and mutations were found to be associated with antibiotic resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Pseudomonas aeruginosa Bacteriophages and Their Clinical Applications.
- Author
-
Alipour-Khezri, Elaheh, Skurnik, Mikael, and Zarrini, Gholamreza
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *CYSTIC fibrosis , *THERAPEUTICS , *BACTERIAL diseases , *DRUG resistance in microorganisms , *PSEUDOMONAS aeruginosa - Abstract
Antimicrobial resistance poses a serious risk to contemporary healthcare since it reduces the number of bacterial illnesses that may be treated with antibiotics, particularly for patients with long-term conditions like cystic fibrosis (CF). People with a genetic predisposition to CF often have recurrent bacterial infections in their lungs due to a buildup of sticky mucus, necessitating long-term antibiotic treatment. Pseudomonas aeruginosa infections are a major cause of CF lung illness, and P. aeruginosa airway isolates are frequently resistant to many antibiotics. Bacteriophages (also known as phages), viruses that infect bacteria, are a viable substitute for antimicrobials to treat P. aeruginosa infections in individuals with CF. Here, we reviewed the utilization of P. aeruginosa bacteriophages both in vivo and in vitro, as well as in the treatment of illnesses and diseases, and the outcomes of the latter. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Neonatal sepsis due to NDM-1 and VIM-2 co-producing Pseudomonas aeruginosa in Morocco.
- Author
-
Daaboul, Dina, Osman, Marwan, Kassem, Issmat I, Yassine, Iman, Girlich, Delphine, Proust, Alexis, Mounir, Chemsi, Zerouali, Khalid, Raymond, Josette, Naas, Thierry, and Oueslati, Saoussen
- Subjects
- *
NEONATAL sepsis , *PSEUDOMONAS aeruginosa , *NEONATAL intensive care units , *CARBAPENEM-resistant bacteria , *WHOLE genome sequencing , *ACINETOBACTER infections , *PSEUDOMONAS aeruginosa infections - Abstract
Background Carbapenem-resistant Pseudomonas aeruginosa are being increasingly described worldwide. Here, we investigated the molecular mechanisms underlying carbapenem resistance in an extremely drug-resistant P. aeruginosa isolate from a neonatal intensive care unit in Morocco. Materials and methods P. aeruginosa strain O82J1 was identified using MALDI-TOF-MS. Carba NP, immunochromatographic assay NG Carba5 and antimicrobial susceptibility testing using disc diffusion and microbroth were performed. Whole-genome sequencing using the Illumina and MinION technologies and different software packages available at the Center of Genomic Epidemiology were used to predict the resistome, sequence type and plasmid types. Results P. aeruginosa O82J1 co-expressed two metallo-β-lactamases, bla NDM-1 and bla VIM-2, and was susceptible to colistin and apramycin only. It belonged to ST773 that is frequently reported worldwide as a high-risk P. aeruginosa clone. The bla VIM-2 gene was integron-borne on a IncP-2 465-kb plasmid, whereas the bla NDM-1 gene was chromosomally encoded and embedded in an integrative conjugative element, probably at the origin of its acquisition. A total of 23 antimicrobial resistance genes were detected including a bla PER-1 ESBL gene, and an 16S-rRNA methyltransferase gene rmtB. Conclusions The isolation of XDR P. aeruginosa isolates expressing several carbapenemases in a neonatal intensive care unit is of great concern due to the reduced treatment options, relying only on colistin, but not recommended in neonates, and apramycin, not yet approved for human therapy. Concerns were further elevated due to the resistance to cefiderocol and ATM/AVI, two novel and last-resort antibiotics recommended to treat infections caused by Gram-negative bacteria, particularly XDR P. aeruginosa in adults. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Pseudomonas aeruginosa infection correlates with high MFI donor-specific antibody development following lung transplantation with consequential graft loss and shortened CLAD-free survival.
- Author
-
Bogyó, Levente Zoltán, Török, Klára, Illés, Zsuzsanna, Szilvási, Anikó, Székely, Bálint, Bohács, Anikó, Pipek, Orsolya, Madurka, Ildikó, Megyesfalvi, Zsolt, Rényi-Vámos, Ferenc, Döme, Balázs, Bogos, Krisztina, Gieszer, Balázs, and Bakos, Eszter
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *LUNG transplantation , *LUNG development , *GRAFT survival , *GRAFT rejection - Abstract
Background: Donor-specific antibodies (DSAs) are common following lung transplantation (LuTx), yet their role in graft damage is inconclusive. Mean fluorescent intensity (MFI) is the main read-out of DSA diagnostics; however its value is often disregarded when analyzing unwanted post-transplant outcomes such as graft loss or chronic lung allograft dysfunction (CLAD). Here we aim to evaluate an MFI stratification method in these outcomes. Methods: A cohort of 87 LuTx recipients has been analyzed, in which a cutoff of 8000 MFI has been determined for high MFI based on clinically relevant data. Accordingly, recipients were divided into DSA-negative, DSA-low and DSA-high subgroups. Both graft survival and CLAD-free survival were evaluated. Among factors that may contribute to DSA development we analyzed Pseudomonas aeruginosa (P. aeruginosa) infection in bronchoalveolar lavage (BAL) specimens. Results: High MFI DSAs contributed to clinical antibody-mediated rejection (AMR) and were associated with significantly worse graft (HR: 5.77, p < 0.0001) and CLAD-free survival (HR: 6.47, p = 0.019) compared to low or negative MFI DSA levels. Analysis of BAL specimens revealed a strong correlation between DSA status, P. aeruginosa infection and BAL neutrophilia. DSA-high status and clinical AMR were both independent prognosticators for decreased graft and CLAD-free survival in our multivariate Cox-regression models, whereas BAL neutrophilia was associated with worse graft survival. Conclusions: P. aeruginosa infection rates are elevated in recipients with a strong DSA response. Our results indicate that the simultaneous interpretation of MFI values and BAL neutrophilia is a feasible approach for risk evaluation and may help clinicians when to initiate DSA desensitization therapy, as early intervention could improve prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Synergic Antibiofilm Effect of Thymol and Zinc Oxide Nanoparticles Conjugated with Thiosemicarbazone on Pathogenic Pseudomonas aeruginosa Strains.
- Author
-
Mokhtari, Hadiseh, Abdulrazaq Alkinani, Tabarek, Ataei-e jaliseh, Somayeh, Shafighi, Tooba, and Salehzadeh, Ali
- Subjects
- *
THYMOL , *ZINC oxide , *PSEUDOMONAS aeruginosa infections , *PSEUDOMONAS aeruginosa , *NANOPARTICLES , *GENTIAN violet - Abstract
Due to the emergence of drug resistance, treating Pseudomonas aeruginosa infections is a major health challenge. In a biofilm, bacteria are usually more resistant to antimicrobials than planktonic growth. Thus, antibiofilm compounds can be employed against bacterial infections. In this study, Zinc oxide (ZnO) nanoparticles (NPs) were prepared and functionalized by glutamic acid (ZnO@Glu). Next, the nanoparticles were conjugated with Thiosemicarbazone (ZnO@Glu- TSC), and their antibiofilm activity in combination with Thymol on P. aeruginosa strains was investigated. Physicochemical characterization by FT-IR and XRD analyses showed that the nanoparticles were synthesized properly and their purity was displayed by EDS mapping. The zeta potential of the NPs was − 7.7 mV which indicates the stability of the NPs. Also, the synthesized particles were in the nano-scale size range. Biofilm formation in P. aeruginosa strains was evaluated using Congo-Red agar assay and the antibacterial effect of Thymol and ZnO@Glu-TSC was also studied. Finally, the antibiofilm potential of Thymol, ZnO@Glu-TSC, and Thymol+ZnO@Glu-TSC NPs was studied by crystal violet staining assay. Thymol and ZnO@Glu-TSC NPs had stronger antibacterial potential in combination, and the minimum inhibitory concentration was 3.12–25.5 µg/mL. Also, the combination of the NPs with Thymol led to biofilm inhibition up to 95%, which was significantly higher than either agent alone. This work revealed that Thymol could enhance the antibacterial and antibiofilm potentials of ZnO@Glu-TSC NPs that provides a new option to combat P. aeruginosa infections after further research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis.
- Author
-
Shields, Ryan K., Horcajada, Juan P., Kamat, Shweta, Irani, Paurus M., Tawadrous, Margaret, and Welte, Tobias
- Subjects
- *
BACTEREMIA , *PSEUDOMONAS aeruginosa infections , *VENTILATOR-associated pneumonia , *PNEUMONIA , *PEDIATRIC therapy - Abstract
Introduction: Ceftazidime-avibactam (CAZ-AVI) is a combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam that is approved for the treatment of pediatric (≥ 3 months) and adult patients with complicated infections including hospital-acquired and ventilator-associated pneumonia (HAP/VAP), and bacteremia. This systematic literature review and meta-analysis (PROSPERO registration: CRD42022362856) aimed to provide a quantitative and qualitative synthesis to evaluate the effectiveness of CAZ-AVI in treating adult patients with bacteremia or nosocomial pneumonia caused by carbapenem-resistant Enterobacterales (non metallo-β-lactamase-producing strains) and multi-drug resistant (MDR) Pseudomonas aeruginosa infections. Methods: The databases included in the search, until November 7, 2022, were Embase and PubMed. A total of 24 studies (retrospective: 22, prospective: 2) with separate outcomes for patients with bacteremia or pneumonia were included. Results: The outcomes assessed were all-cause mortality, clinical cure, and microbiological cure. Qualitative (24 studies) and quantitative (8/24 studies) syntheses were performed. The quality of the studies was assessed using the MINORS checklist and the overall risk of bias was moderate to high. Conclusions: In studies included in the meta-analysis, lower all-cause mortality for patients with bacteremia (OR = 0.30, 95% CI 0.19–0.46) and improved rates of clinical cure for patients with bacteremia (OR = 4.90, 95% CI 2.60–9.23) and nosocomial pneumonia (OR = 3.20, 95% CI 1.55–6.60) was observed in the CAZ-AVI group compared with the comparator group. Data provided here may be considered while using CAZ-AVI for the treatment of patients with difficult-to-treat infections. Systematic Review Registration: PROSPERO CRD42022362856. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Recessively Inherited Deficiency of Secreted WFDC2 (HE4) Causes Nasal Polyposis and Bronchiectasis.
- Author
-
Dougherty, Gerard W., Ostrowski, Lawrence E., Nöthe-Menchen, Tabea, Raidt, Johanna, Schramm, Andre, Olbrich, Heike, Yin, Weining, Sears, Patrick R., Dang, Hong, Smith, Amanda J., Beule, Achim G., Hjeij, Rim, Rutjes, Niels, Haarman, Eric G., Maas, Saskia M., Ferkol, Thomas W., Noone, Peadar G., Olivier, Kenneth N., Bracht, Diana C., and Barbry, Pascal
- Subjects
BRONCHIECTASIS ,NASAL polyps ,CILIARY motility disorders ,PSEUDOMONAS aeruginosa infections ,PRIMARY immunodeficiency diseases ,IDIOPATHIC diseases - Abstract
Rationale: Bronchiectasis is a pathological dilatation of the bronchi in the respiratory airways associated with environmental or genetic causes (e.g., cystic fibrosis, primary ciliary dyskinesia, and primary immunodeficiency disorders), but most cases remain idiopathic. Objectives: To identify novel genetic defects in unsolved cases of bronchiectasis presenting with severe rhinosinusitis, nasal polyposis, and pulmonary Pseudomonas aeruginosa infection. Methods: DNA was analyzed by next-generation or targeted Sanger sequencing. RNA was analyzed by quantitative PCR and single-cell RNA sequencing. Patient-derived cells, cell cultures, and secretions (mucus, saliva, seminal fluid) were analyzed by Western blotting and immunofluorescence microscopy, and mucociliary activity was measured. Blood serum was analyzed by electrochemiluminescence immunoassay. Protein structure and proteomic analyses were used to assess the impact of a disease-causing founder variant. Measurements and Main Results: We identified biallelic pathogenic variants in WAP four-disulfide core domain 2 (WFDC2) in 11 individuals from 10 unrelated families originating from the United States, Europe, Asia, and Africa. Expression of WFDC2 was detected predominantly in secretory cells of control airway epithelium and also in submucosal glands. We demonstrate that WFDC2 is below the limit of detection in blood serum and hardly detectable in samples of saliva, seminal fluid, and airway surface liquid from WFDC2-deficient individuals. Computer simulations and deglycosylation assays indicate that the disease-causing founder variant p.Cys49Arg structurally hampers glycosylation and, thus, secretion of mature WFDC2. Conclusions:WFDC2 dysfunction defines a novel molecular etiology of bronchiectasis characterized by the deficiency of a secreted component of the airways. A commercially available blood test combined with genetic testing allows its diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Comparison of Different Methods for Assaying the In Vitro Activity of Cefiderocol against Carbapenem-Resistant Pseudomonas aeruginosa Strains: Influence of Bacterial Inoculum.
- Author
-
García-Rivera, Celia, Sánchez-Bautista, Antonia, Parra-Grande, Mónica, Ricart-Silvestre, Andrea, Ventero, María Paz, Tyshkovska, Iryna, Merino, Esperanza, and Rodríguez Díaz, Juan Carlos
- Subjects
CARBAPENEM-resistant bacteria ,PSEUDOMONAS aeruginosa infections ,PSEUDOMONAS aeruginosa ,DRUG efficacy ,DRUG resistance in bacteria - Abstract
Carbapenem-resistant Pseudomonas aeruginosa infections represent a critical public health concern, highlighting the need for the development of effective antibiotics. Cefiderocol demonstrated potent in vitro activity against Pseudomonas aeruginosa, particularly in strains that are resistant to other drugs. However, concerns regarding the emergence of drug-resistant strains persist. This study, conducted with 109 carbapenem-resistant Pseudomonas aeruginosa strains from the Spanish Hospital (Dr. Balmis, Alicante). The study evaluated susceptibility to cefiderocol in comparison to alternative antibiotics and including their susceptibility to bacterial inoculum, while assessing various testing methods. Our findings revealed high susceptibility to cefiderocol against carbapenem-resistant strains, with only 2 of 109 strains exhibiting resistance. Comparative analysis demonstrated superiority of cefiderocol towards alternative antibiotics. Both the E-test and disk-diffusion methods showed 100% concordance with the microdilution method in classifying strains as susceptible or resistant. However, 4.6% (5/109) of disc zone diameters fell within the technical uncertainty zone, so the E-test technique was found to be more useful in routine clinical practice. Additionally, escalating bacterial inoculum correlated with decreases in vitro activity, so this parameter should be adjusted very carefully in in vivo studies. This study underscores cefiderocol's potential as a therapeutic option for carbapenem-resistant Pseudomonas aeruginosa infections. However, the emergence of drug-resistant strains emphasizes the critical need for a wise use of antibiotics and a continuous monitoring of resistance to antibiotics. Based on our in vitro data, further investigation concerning the impact of bacterial inoculum on drug efficacy is warranted in order to detect resistance mechanisms and optimize treatment strategies, thereby mitigating the risk of resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Impact of Growth Conditions on High-Throughput Identification of Repurposing Drugs for Pseudomonas aeruginosa Cystic Fibrosis Lung Infections.
- Author
-
Di Bonaventura, Giovanni, Lupetti, Veronica, and Pompilio, Arianna
- Subjects
PSEUDOMONAS aeruginosa infections ,DRUG repositioning ,HIGH throughput screening (Drug development) ,CYSTIC fibrosis ,ANTIBACTERIAL agents - Abstract
Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) patients represent a therapeutic challenge due to antibiotic resistance. Repurposing existing drugs is a promising approach for identifying new antimicrobials. A crucial factor in successful drug repurposing is using assay conditions that mirror the site of infection. Here, the impact of growth conditions on the anti-P. aeruginosa activity of a library of 3386 compounds was evaluated. To this, after 24 h exposure, the survival rate of CF P. aeruginosa RP73 planktonic cells was assessed spectrophotometrically under "CF-like" (artificial CF sputum, pH 6.8, 5% CO
2 ) and enriched (Tryptone Soya Broth, pH 7.2, and aerobiosis) conditions. Among non-antibiotic compounds (n = 3127), 13.4% were active regardless of growth conditions, although only 3.2% had comparable activity; 4% and 6.2% were more active under CF-like or enriched conditions, respectively. Interestingly, 22.1% and 26.6% were active exclusively under CF-like and enriched conditions, respectively. Notably, 7 and 12 hits caused 100% killing under CF-like and enriched conditions, respectively. Among antibiotics (n = 234), 42.3% were active under both conditions, although only 18.4% showed comparable activity; 9.4% and 14.5% were more active under CF-like and enriched conditions, respectively. Interestingly, 23% and 16.6% were active exclusively under CF-like and enriched conditions, respectively. Sulphonamides showed higher activity under CF-like conditions, whereas tetracyclines, fluoroquinolones, and macrolides were more effective under enriched settings. Our findings indicated that growth conditions significantly affect the anti-P. aeruginosa activity of antibiotics and non-antibiotic drugs. Consequently, repurposing studies and susceptibility tests should be performed under physicochemical conditions that the pathogen tackles at the site of infection. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
32. Modification and Synergistic Studies of a Novel Frog Antimicrobial Peptide against Pseudomonas aeruginosa Biofilms.
- Author
-
Liu, Xinze, Shi, Daning, Cheng, Shiya, Chen, Xiaoling, Ma, Chengbang, Jiang, Yangyang, Wang, Tao, Chen, Tianbao, Shaw, Chris, Wang, Lei, and Zhou, Mei
- Subjects
ANTIMICROBIAL peptides ,PSEUDOMONAS aeruginosa infections ,PEPTIDES ,ANTI-infective agents ,ANTIBIOTIC overuse - Abstract
The overuse of traditional antibiotics has resulted in bacterial resistance and seriously compromised the therapeutic efficacy of traditional antibiotics, making the exploration of new antimicrobials particularly important. Several studies have shown that bioactive peptides have become an important source of new antimicrobial drugs due to their broad-spectrum antibacterial action and lack of susceptibility to resistance. In this study, a novel bioactive peptide Nigrosin-6VL was characterised from the skin secretion of the golden cross band frog, Odorrana andersonii, by using the 'shotgun' cloning strategy. Modifications on the Rana Box of Nigrosin-6VL revealed its critical role in antimicrobial functions. The peptide analogue, 2170-2R, designed to preserve the Rana Box structure while enhancing cationicity, exhibited improved therapeutic efficacy, particularly against Gram-negative bacteria, with a therapeutic value of 45.27. Synergistic studies demonstrated that 2170-2R inherits the synergistic antimicrobial activities of the parent peptides and effectively enhances the antimicrobial capacity of cefepime and gentamicin against both planktonic cells and biofilms. Specifically, 2170-2R can synergise effectively with cefepime and gentamicin against different strains of P. aeruginosa biofilms. Consequently, 2170-2R holds promise as a potent antimicrobial agent developed to combat infections induced by Pseudomonas aeruginosa. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Extracellular vesicles released by host epithelial cells during Pseudomonas aeruginosa infection function as homing beacons for neutrophils.
- Author
-
Ayilam Ramachandran, Rajalakshmy, Lemoff, Andrew, and Robertson, Danielle M.
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *EPITHELIAL cells , *NEUTROPHILS , *EXTRACELLULAR vesicles , *QUORUM sensing , *GEL permeation chromatography , *PSEUDOMONAS diseases - Abstract
Background: Pseudomonas aeruginosa (PA) is an opportunistic pathogen that can cause sight threatening infections in the eye and fatal infections in the cystic fibrosis airway. Extracellular vesicles (EVs) are released by host cells during infection and by the bacteria themselves; however, there are no studies on the composition and functional role of host-derived EVs during PA infection of the eye or lung. Here we investigated the composition and capacity of EVs released by PA infected epithelial cells to modulate innate immune responses in host cells. Methods: Human telomerase immortalized corneal epithelial cells (hTCEpi) cells and human telomerase immortalized bronchial epithelial cells (HBECs) were treated with a standard invasive test strain of Pseudomonas aeruginosa, PAO1, for 6 h. Host derived EVs were isolated by qEV size exclusion chromatography. EV proteomic profiles during infection were compared using mass spectrometry and functional studies were carried out using hTCEpi cells, HBECs, differentiated neutrophil-like HL-60 cells, and primary human neutrophils isolated from peripheral blood. Results: EVs released from PA infected corneal epithelial cells increased pro-inflammatory cytokine production in naïve corneal epithelial cells and induced neutrophil chemotaxis independent of cytokine production. The EVs released from PA infected bronchial epithelial cells were also chemotactic although they failed to induce cytokine secretion from naïve HBECs. At the proteomic level, EVs derived from PA infected corneal epithelial cells exhibited lower complexity compared to bronchial epithelial cells, with the latter having reduced protein expression compared to the non-infected control. Conclusions: This is the first study to comprehensively profile EVs released by corneal and bronchial epithelial cells during Pseudomonas infection. Together, these findings show that EVs released by PA infected corneal and bronchial epithelial cells function as potent mediators of neutrophil migration, contributing to the exuberant neutrophil response that occurs during infection in these tissues. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Upscaling and Risk Evaluation of the Synthesis of the 3,5-Diamino-1H-Pyrazole, Disperazol.
- Author
-
Jansen, Charlotte Uldahl, Grier, Katja Egeskov, Andersen, Jens Bo, Hultqvist, Louise Dahl, Nilsson, Martin, Moser, Claus, Graz, Michael, Tolker-Nielsen, Tim, Givskov, Michael, and Qvortrup, Katrine
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *RISK assessment , *FLOW chemistry , *CORTISONE - Abstract
This paper presents the work performed to transition a lab-scale synthesis (1 g) to a large-scale (400 g) synthesis of the 3-5-diamino-1H-Pyrazole Disperazol, a new pharmaceutical for treatment of antibiotic-resistant Pseudomonas aeruginosa biofilm infections. The potentially hazardous diazotisation step in the lab-scale synthesis was transformed to a safe and easy-to-handle flow chemistry step. Additionally, the paper presents an OSHA-recommended safety assessment of active compound E, as performed by Fauske and Associates, LLC, Burr Ridge, IL, USA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Surface modified niosomal quercetin with cationic lipid: an appropriate drug delivery system against Pseudomonas aeruginosa Infections.
- Author
-
Hemmati, Jaber, Chiani, Mohsen, Chegini, Zahra, Seifalian, Alexander, and Arabestani, Mohammad Reza
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *DRUG delivery systems , *CATIONIC lipids , *QUERCETIN , *FIELD emission electron microscopy , *CYTOCOMPATIBILITY - Abstract
The Increase in infections caused by resistant strains of Pseudomonas aeruginosa poses a formidable challenge to global healthcare systems. P. aeruginosa is capable of causing severe human infections across diverse anatomical sites, presenting considerable therapeutic obstacles due to its heightened drug resistance. Niosomal drug delivery systems offer enhanced pharmaceutical potential for loaded contents due to their desirable properties, mainly providing a controlled-release profile. This study aimed to formulate an optimized niosomal drug delivery system incorporating stearylamine (SA) to augment the anti-bacterial and anti-biofilm activities of quercetin (QCT) against both standard and clinical strains of P. aeruginosa. QCT-loaded niosome (QCT-niosome) and QCT-loaded SA- niosome (QCT-SA- niosome) were synthesized by the thin-film hydration technique, and their physicochemical characteristics were evaluated by field emission scanning electron microscopy (FE-SEM), zeta potential measurement, entrapment efficacy (EE%), and in vitro release profile. The anti-P. aeruginosa activity of synthesized niosomes was assessed using minimum inhibitory and bactericidal concentrations (MICs/MBCs) and compared with free QCT. Additionally, the minimum biofilm inhibitory and eradication concentrations (MBICs/MBECs) were carried out to analyze the ability of QCT-niosome and QCT-SA-niosome against P. aeruginosa biofilms. Furthermore, the cytotoxicity assay was conducted on the L929 mouse fibroblasts cell line to evaluate the biocompatibility of the formulated niosomes. FE-SEM analysis revealed that both synthesized niosomal formulations exhibited spherical morphology with different sizes (57.4 nm for QCT-niosome and 178.9 nm for QCT-SA-niosome). The EE% for cationic and standard niosomal formulations was reported at 75.9% and 59.6%, respectively. Both formulations showed an in vitro sustained-release profile, and QCT-SA-niosome exhibited greater stability during a 4-month storage time compared to QCT-niosome. Microbial experiments indicated that both prepared formulations had higher anti-bacterial and anti-biofilm activities than free QCT. Also, the QCT-SA-niosome exhibited greater reductions in MIC, MBC, MBIC, and MBEC values compared to the QCT-niosome at equivalent concentrations. This study supports the potential of QCT-niosome and QCT-SA-niosome as effective agents against P. aeruginosa infections, manifesting significant anti-bacterial and anti-biofilm efficacy alongside biocompatibility with L929 cell lines. Furthermore, our results suggest that optimized QCT-niosome with cationic lipids could efficiently target P. aeruginosa cells with negligible cytotoxic effect. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Systemic antibiotics for Pseudomonas aeruginosa infection in outpatients with non-hospitalised exacerbations of pre-existing lung diseases: a randomised clinical trial.
- Author
-
Eklöf, Josefin, Alispahic, Imane Achir, Armbruster, Karin, Lapperre, Therese Sophie, Browatzki, Andrea, Overgaard, Rikke Holmen, Harboe, Zitta Barrella, Janner, Julie, Moberg, Mia, Ulrik, Charlotte Suppli, Andreassen, Helle Frost, Weinreich, Ulla Møller, Kjærgaard, Jakob Lyngby, Villadsen, Jenny, Fenlev, Camilla Sund, Jensen, Torben Tranborg, Christensen, Christina Wellendorph, Bangsborg, Jette, Ostergaard, Christian, and Ghathian, Khaled Saoud Ali
- Subjects
- *
BRONCHIECTASIS , *PSEUDOMONAS aeruginosa infections , *LUNG diseases , *COVID-19 pandemic , *CLINICAL trials , *OUTPATIENTS - Abstract
Background: The effect of dual systemic antibiotic therapy against Pseudomonas aeruginosa in patients with pre-existing lung disease is unknown. To assess whether dual systemic antibiotics against P. aeruginosa in outpatients with COPD, non-cystic fibrosis (non-CF) bronchiectasis, or asthma can improve outcomes. Methods: Multicenter, randomised, open-label trial conducted at seven respiratory outpatient clinics in Denmark. Outpatients with COPD, non-CF bronchiectasis, or asthma with a current P. aeruginosa-positive lower respiratory tract culture (clinical routine samples obtained based on symptoms of exacerbation not requiring hospitalisation), regardless of prior P. aeruginosa-status, no current need for hospitalisation, and at least two moderate or one hospitalisation-requiring exacerbation within the last year were eligible. Patients were assigned 1:1 to 14 days of dual systemic anti-pseudomonal antibiotics or no antibiotic treatment. Primary outcome was time to prednisolone or antibiotic-requiring exacerbation or death from day 20 to day 365. Results: The trial was stopped prematurely based in lack of recruitment during the COVID-19 pandemic, this decision was endorsed by the Data and Safety Monitoring Board. Forty-nine outpatients were included in the study. There was a reduction in risk of the primary outcome in the antibiotic group compared to the control group (HR 0.51 (95%CI 0.27–0.96), p = 0.037). The incidence of admissions with exacerbation within one year was 1.1 (95%CI 0.6–1.7) in the dual antibiotic group vs. 2.9 (95%CI 1.3–4.5) in the control group, p = 0.037. Conclusions: Use of dual systemic antibiotics for 14 days against P. aeruginosa in outpatients with chronic lung diseases and no judged need for hospitalisation, improved clinical outcomes markedly. The main limitation was the premature closure of the trial. Trial Registration: ClinicalTrials.gov, NCT03262142, registration date 2017–08-25. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. A specific innate immune response silences the virulence of Pseudomonas aeruginosa in a latent infection model in the Drosophila melanogaster host.
- Author
-
Chen, Jing, Lin, Guiying, Ma, Kaiyu, Li, Zi, Liégeois, Samuel, and Ferrandon, Dominique
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *DROSOPHILA melanogaster , *LATENT infection , *PSEUDOMONAS aeruginosa , *IMMUNE response , *VIRULENCE of bacteria , *WOLBACHIA - Abstract
Microbial pathogenicity often depends on the route of infection. For instance, P. aeruginosa or S. marcescens cause acute systemic infections when low numbers of bacteria are injected into D. melanogaster flies whereas flies succumb much slower to the continuous ingestion of these pathogens, even though both manage to escape from the gut compartment and reach the hemocoel. Here, we have developed a latent P. aeruginosa infection model by feeding flies on the bacteria for a short period. The bacteria stably colonize internal tissues yet hardly cause any damage since latently-infected flies live almost as long as noninfected control flies. The apparently dormant bacteria display particular characteristics in terms of bacterial colony morphology, composition of the outer cell wall, and motility. The virulence of these bacteria can however be reactivated upon wounding the host. We show that melanization but not the cellular or the systemic humoral response is the predominant host defense that establishes latency and may coerce the bacteria to a dormant state. In addition, the lasting activation of the melanization responses in latently-infected flies provides a degree of protection to the host against a secondary fungal infection. Latent infections by an ingested pathogen protects against a variety of homologous or heterologous systemic secondary infectious challenges, a situation previously described for the endosymbiotic Wolbachia bacteria, a guard against viral infections. Author summary: Environmentally ubiquitous bacteria have acquired extensive abilities to adapt to variable environments, bestowing to some of them the potential to become opportunistic pathogens. This may translate into distinct infection modes according to the route of entry. Whereas Pseudomonas aeruginosa is considered to have two major modes of infection, acute by planktonic cells or chronic through the establishment of biofilms, we report here a novel type of infection whereby ingested bacteria escape from the digestive tract and silently colonize tissues as single cells without strongly affecting the lifespan of the Drosophila host. The bacteria appear to be dormant, a feature shared with persister cells that elude the action of antibiotics. They are characterized by distinct bacterial and colony morphologies, cell surface and motility properties. Their virulence program can nevertheless be reactivated spontaneously or upon injury. We also report that an important host defense of invertebrates, melanization, is activated upon escape of the bacteria into the internal milieu. This activation not only promotes the dormancy of the colonizing bacteria but also protects the host to some degree against secondary infections. As P. aeruginosa is a member of the microbiota of a sizable fraction of human populations, these discoveries may become medically relevant. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Developing antibacterial peptides as a promising therapy for combating antibiotic-resistant Pseudomonas aeruginosa infections.
- Author
-
Darwish, Rula M. and Salama, Ali H.
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *EXOTOXIN , *ELECTROSPRAY ionization mass spectrometry , *HIGH performance liquid chromatography , *PEPTIDES , *ANTIBACTERIAL agents - Abstract
Background and Aim: Antibiotic-resistant Pseudomonas aeruginosa poses a serious health threat. This study aimed to investigate the antibacterial activity of peptide KW-23 against drug-resistant P. aeruginosa and its potential for enhancing the efficacy of conventional antibiotics. Materials and Methods: KW-23 was synthesized from nine amino acids, specifically three tryptophans and three lysines. The purity of the substance was analyzed using reverse-phase high-performance liquid chromatography. The peptide was identified through mass spectrometry using electrospray ionization. The minimum inhibitory concentration (MIC) values of KW-23 in combination with conventional antibiotics against control and multidrug-resistant P. aeruginosa were determined utilizing broth microdilution. The erythrocyte hemolytic assay was used to measure toxicity. The KW-23 effect was analyzed using the time-kill curve. Results: The peptide exhibited strong antibacterial activity against control and multidrug-resistant strains of P. aeruginosa, with MICs of 4.5 μg/mL and 20 μg/mL, respectively. At higher concentration of 100 μg/mL, KW-23 exhibited a low hemolytic impact, causing no more than 3% damage to red blood. The cytotoxicity assay demonstrates KW-23's safety, while the time-kill curve highlights its rapid and sustained antibacterial activity. The combination of KW-23 and gentamicin exhibited synergistic activity against both susceptible and resistant P. aeruginosa, with fractional inhibitory concentration index values of 0.07 and 0.27, respectively. Conclusion: The KW-23 synthesized in the laboratory significantly combats antibiotic-resistant P. aeruginosa. Due to its strong antibacterial properties and low toxicity to cells, KW-23 is a promising alternative to traditional antibiotics in combating multidrug-resistant bacteria. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Inhibition of Virulence Properties of Pathogenic Pseudomonas aeruginosa by Rutin-Loaded Chitosan Nanoparticles.
- Author
-
Zahmatkesh, Hossein, Esnaashari, Fatemeh, and Zamani, Hojjatolah
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *NANOPARTICLES , *EXOTOXIN , *CHITOSAN , *X-ray diffraction , *DRUG resistance in bacteria - Abstract
Due to biofilm formation and the development of antibiotic resistance, alternative approaches are required to counter Pseudomonas aeruginosa infections. Additionally, P. aeruginosa produces several virulence factors that play a crucial role in chronic infections. The current study aimed to synthesize rutin-loaded chitosan nanoparticles (RUT-CS NPs) and investigate their antibacterial potential against pathogenic P. aeruginosa strains. RUT-CS NPs were synthesized through ionic gelation technique and characterized using FTIR, XRD, DLS, Zeta, SEM, and TEM analyses. The characterization of the synthesized NPs revealed an amorphous structure with a diameter ranging from 230 to 280 nm. The motility of P. aeruginosa, including swarming, swimming, and twitching, was notably diminished by RUT-CS NPs. Furthermore, the NPs exhibited a substantial biofilm inhibitory effect on P. aeruginosa. Moreover, RUT-CS NPs decreased bacterial pyocyanin levels and proteolytic activity. Findings from the current research demonstrate the potential of RUT-CS NPs as a promising novel treatment option for managing P. aeruginosa infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Antipseudomonal Antibiotics in Diabetic Foot Infections: A Practical Perspective From a Community Hospital.
- Author
-
Lau, Janice, Huang, Joanne, and Escobar, Zahra Kassamali
- Subjects
- *
FOOT diseases , *DIABETIC foot , *ANTIBIOTICS , *INFECTION , *JOINT infections , *PSEUDOMONAS aeruginosa infections - Abstract
A recent study examined the prescribing practices for diabetic foot infections (DFIs) in the United States. The study found that there was a high rate of discordant use of antipseudomonal therapy compared to the actual prevalence of Pseudomonas aeruginosa (PsA) in culture. Risk factors for PsA isolation included immunocompromised status and previous outpatient treatment failure. The study suggests that antimicrobial stewardship programs should focus on avoiding unnecessary antipseudomonal antibiotics and emphasizes the need for surgical interventions and preventative care in addition to empiric antibiotic treatment. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
41. In Vitro Antibiofilm Activity of Fosfomycin Alone and in Combination with Other Antibiotics against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa.
- Author
-
Slade-Vitković, Mia, Batarilo, Ivanka, Bielen, Luka, Maravić-Vlahoviček, Gordana, and Bedenić, Branka
- Subjects
- *
IMIPENEM , *CEFTAZIDIME , *PSEUDOMONAS aeruginosa , *PSEUDOMONAS aeruginosa infections , *FOSFOMYCIN , *LACTAMS , *ANTIBIOTICS , *PROTEIN synthesis , *COLISTIN - Abstract
Background: Due to its rapid resistance development and ability to form biofilms, treatment of Pseudomonas aeruginosa infections is becoming more complicated by the day. Drug combinations may help reduce both resistance and biofilm formation. Methods: Using the microtiter plate assay, we investigated the in vitro inhibition of biofilm formation and the disruption of preformed biofilms in multidrug-resistant and extensively drug-resistant clinical isolates of P. aeruginosa in the presence of peak plasma levels of eight antipseudomonal antibiotics alone and in combination with fosfomycin: ceftazidime, piperacillin/tazobactam, cefepime, imipenem, gentamicin, amikacin, ciprofloxacin and colistin. Results: Combination therapy was significantly superior to monotherapy in its inhibition of biofilm formation. The highest inhibition rates were observed for combinations with colistin, cefepime and ceftazidime. Conclusion: Our results support fosfomycin combination therapy as an enhanced prophylactic option. Moreover, combinations with β-lactam antibiotics and colistin demonstrated a more potent inhibition effect on biofilm formation than protein synthesis inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Detection of Exoenzyme Effectors and Determination The MIC of Antibiotics for Pseudomonas Aeruginosa Isolated from Ear Infections Patients in Basrah Province, Iraq.
- Author
-
Waham, Ayad Abdulhadi and Naser, Lina A.
- Subjects
- *
EAR infections , *PSEUDOMONAS aeruginosa , *PSEUDOMONAS aeruginosa infections , *VIRULENCE of bacteria , *ANTIBIOTICS - Abstract
Ear infections are a common health problem, the most common microorganism which cause of infection is Pseudomonas aeruginosa. The study aimed to detection for bacterium ability of virulence factors production, molecular detection on that Exoenzyme effectors. The results of P. aeruginosa is the most type at18.62%. This bacterium was had a high level of resistance to the Ticarcillin antibiotic at 73.69%, were 10% of isolates (MDR), 42% (XDR) and 5% (PDR), production was each of the biofilm at 89.47%, protease enzyme at 79.94%, and Metallo betalactamase at 47.36%. Presence of exoenzyme genes (exoS:57.89%, exoT: 84.21%, exoU: 73.68% and exoY: 89.47%). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Phylogenetic Tracing of Evolutionarily Conserved Zonula Occludens Toxin Reveals a "High Value" Vaccine Candidate Specific for Treating Multi-Strain Pseudomonas aeruginosa Infections.
- Author
-
Benyamini, Payam
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *TIGHT junctions , *TOXINS , *EMERGING infectious diseases , *TERTIARY structure - Abstract
Extensively drug-resistant Pseudomonas aeruginosa infections are emerging as a significant threat associated with adverse patient outcomes. Due to this organism's inherent properties of developing antibiotic resistance, we sought to investigate alternative strategies such as identifying "high value" antigens for immunotherapy-based purposes. Through extensive database mining, we discovered that numerous Gram-negative bacterial (GNB) genomes, many of which are known multidrug-resistant (MDR) pathogens, including P. aeruginosa, horizontally acquired the evolutionarily conserved gene encoding Zonula occludens toxin (Zot) with a substantial degree of homology. The toxin's genomic footprint among so many different GNB stresses its evolutionary importance. By employing in silico techniques such as proteomic-based phylogenetic tracing, in conjunction with comparative structural modeling, we discovered a highly conserved intermembrane associated stretch of 70 amino acids shared among all the GNB strains analyzed. The characterization of our newly identified antigen reveals it to be a "high value" vaccine candidate specific for P. aeruginosa. This newly identified antigen harbors multiple non-overlapping B- and T-cell epitopes exhibiting very high binding affinities and can adopt identical tertiary structures among the least genetically homologous P. aeruginosa strains. Taken together, using proteomic-driven reverse vaccinology techniques, we identified multiple "high value" vaccine candidates capable of eliciting a polarized immune response against all the P. aeruginosa genetic variants tested. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Botanical Control of Multiple Drug Resistant Pseudomonas aeruginosa infection in Clarias gariepinus.
- Author
-
Ikele, Chika Bright, Ikele, Onyeka Michael, Oparaku, Nkiruka Francisca, Obiezue, Rose Nduka, Okoye, Ikem Chris, Promise, George, Uche, Nnadi, and Arinze, Adaeze
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *CLARIAS gariepinus , *PSEUDOMONAS diseases , *MORINGA oleifera , *OPPORTUNISTIC infections , *FISH feeds , *PSEUDOMONAS aeruginosa - Abstract
Pseudomonas aeruginosa is a Gram-negative, rod-shaped bacterium which can cause opportunistic infections in fishes. Ethanolic leaf extract of Moringa oleifera was used in the treatment of Pseudomonas aeruginosa infected Clarias gariepinus for a period of 10 days. Pathogen-free Clarias gariepinus fingerlings (n=120) were randomly distributed into four different groups (A-D). Group A, Infected Clarias gariepinus without treatment; group B, Infected Clarias gariepinus treated with ciprofloxacin 250 mg/mL); group C, Infected Clarias gariepinus treated with 500 mg/L Moringa oleifera extract; and group D, Infected Clarias gariepinus treated with 1500 mg/L Moringa oleifera extract. A 0.1 mL aliquot of 7.2x105 CFU/mL of Pseudomonas aeruginosa culture was intra-peritoneally injected into the body of the fingerlings to induce infection. The gill of fish was excised, homogenized and centrifuged to ascertain oxidative stress, while histological examination followed thereafter. The minimum inhibitory concentration of the ethanol extract was 125 mg/mL while the minimum bactericidal concentration was at 500 mg/mL. Gross morphology examination showed hemorrhage in the gill and mouth, and swollen abdomen, after 72 h of infection. The weight of Pseudomonas aeruginosa infected Clarias gariepinus before and after treatment showed no significant differences (P > 0.05) among the groups. There was significant (p<0.05) reduction in oxidative stress parameters examined. Histopathological changes noticed were minor hemorrhage epitheliocystis and damaged gill lamella. Total bacterial count showed a reduction in the Pseudomonas load in groups C and D over the period of study thus, indicating strong potentials of Moringa oleifera in the control of fish Pseudomonas infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Porcine model of a complicated skin and soft tissue infection caused by Pseudomonas aeruginosa.
- Author
-
LIPOVY, BRETISLAV, VACEK, LUKAS, KLEKNEROVA, DOMINIKA POLASTIK, JEKLOVA, EDITA, LISKOVA, LENKA, HOLOUBEK, JAKUB, MATYSKOVA, DOMINIKA, and RUZICKA, FILIP
- Subjects
- *
SOFT tissue infections , *PSEUDOMONAS aeruginosa infections , *PSEUDOMONAS aeruginosa , *DRUG resistance in microorganisms , *WOUND healing - Abstract
Pseudomonas aeruginosa poses a significant threat to both immunocompetent and immunocompromised individuals, often resulting in life-threatening infections. With increasing antimicrobial resistance, novel therapeutic strategies are urgently needed. Although animal models are crucial for preclinical studies, limited data are available for porcine models, more specifically for P. aeruginosa complicated skin and soft tissue infections (cSSTIs). This study presents a novel porcine model inducing and sustaining cSSTI for 14 days. Six pigs (120 wounds) were used for the development of infections, and within this group, two pigs (40 wounds) were used to evaluate the progression of the cSSTI infection. The model demonstrated bacterial loads of more than 107 CFU/gram of tissue or higher. The cSSTI fully developed within three days and remained well above these levels until day 14 post-infection. Due to the immunocompetence of this model, all the immunological processes associated with the response to the presence of infection and the wound healing process are preserved. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Neutrophils and galectin-3 defend mice from lethal bacterial infection and humans from acute respiratory failure.
- Author
-
Das, Sudipta, Kaminski, Tomasz W., Schlegel, Brent T., Bain, William, Hu, Sanmei, Patel, Akruti, Kale, Sagar L., Chen, Kong, Lee, Janet S., Mallampalli, Rama K., Kagan, Valerian E., Rajasundaram, Dhivyaa, McVerry, Bryan J., Sundd, Prithu, Kitsios, Georgios D., Ray, Anuradha, and Ray, Prabir
- Subjects
ADULT respiratory distress syndrome ,GALECTINS ,BACTERIAL diseases ,NEUTROPHILS ,PSEUDOMONAS aeruginosa infections - Abstract
Respiratory infection by Pseudomonas aeruginosa, common in hospitalized immunocompromised and immunocompetent ventilated patients, can be life-threatening because of antibiotic resistance. This raises the question of whether the host's immune system can be educated to combat this bacterium. Here we show that prior exposure to a single low dose of lipopolysaccharide (LPS) protects mice from a lethal infection by P. aeruginosa. LPS exposure trained the innate immune system by promoting expansion of neutrophil and interstitial macrophage populations distinguishable from other immune cells with enrichment of gene sets for phagocytosis- and cell-killing-associated genes. The cell-killing gene set in the neutrophil population uniquely expressed Lgals3, which encodes the multifunctional antibacterial protein, galectin-3. Intravital imaging for bacterial phagocytosis, assessment of bacterial killing and neutrophil-associated galectin-3 protein levels together with use of galectin-3-deficient mice collectively highlight neutrophils and galectin-3 as central players in LPS-mediated protection. Patients with acute respiratory failure revealed significantly higher galectin-3 levels in endotracheal aspirates (ETAs) of survivors compared to non-survivors, galectin-3 levels strongly correlating with a neutrophil signature in the ETAs and a prognostically favorable hypoinflammatory plasma biomarker subphenotype. Taken together, our study provides impetus for harnessing the potential of galectin-3-expressing neutrophils to protect from lethal infections and respiratory failure. This study reports training by lipopolysaccharide to expand neutrophils expressing the anti-bacterial galectin-3 protein defending mice from a lethal bacterial infection, a similar signature associated with survivors of respiratory failure in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Antimicrobial Peptide Reduces Cytotoxicity and Inflammation in Canine Epidermal Keratinocyte Progenitor Cells Induced by Pseudomonas aeruginosa Infection.
- Author
-
Hyun, Jae-Eun and Hwang, Cheol-Yong
- Subjects
PSEUDOMONAS aeruginosa infections ,ANTIMICROBIAL peptides ,PROGENITOR cells ,CYTOTOXINS ,KERATINOCYTES ,PEPTIDE antibiotics - Abstract
Simple Summary: Pseudomonas aeruginosa is a representative Gram-negative bacterial species that causes chronic deep infections in the skin and ears of dogs. Increasing P. aeruginosa antibiotic resistance in human and veterinary medicine requires the identification of new antibacterial substances. In this study, we demonstrated the antibiotic and antibiofilm activities of synthetic canine antimicrobial peptides (AMPs) against P. aeruginosa. In addition, it was confirmed that AMPs significantly reduced the cell toxicity induced by P. aeruginosa and reduced the P. aeruginosa lipopolysaccharide (LPS)-induced inflammation in canine keratinocytes. These findings suggest the potential of AMPs as a new antibacterial agent for the P. aeruginosa infection of canine skin. The direct effects and antimicrobial activity of synthetic antimicrobial peptides (AMPs) obtained from dogs, including cBD, cBD103, and cCath, against P. aeruginosa wild-type strain PAO1 and canine keratinocytes were analyzed. Antibacterial effects on planktonic bacteria were assessed by determining the minimum bactericidal concentrations (MBCs) of AMPs and by a time-kill assay. Antibiofilm effects were assessed using the microtiter plate assay. We also evaluated the effects of AMPs on cell cytotoxicity and host immune response induced by stimulating canine epidermal keratinocyte progenitor (CPEK) cells with PAO1 and its LPS. cBD, cBD103, and cCath all exhibited dose-dependent antimicrobial and antibiofilm effects. In particular, 25 μg/mL cBD103 showed rapid bactericidal activity within 60 min and inhibited biofilm formation. In addition, pretreatment with cBD103 (25 µg/mL) and cCath (50 µg/mL) 1 h before stimulation significantly reduced the cytotoxicity of the CPEK cells by PAO1 and LPS-induced IL-6 and TNF-a expressions. cBD had little effect on the response to PAO1 and LPS in the cells. These results indicate the therapeutic potential of AMPs in P. aeruginosa skin infections. However, further studies on the mechanism of action of AMPs in keratinocytes and clinical trials are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. VX-702 Ameliorates the Severity of Sepsis-Associated Acute Kidney Injury by Downregulating Inflammatory Factors in Macrophages.
- Author
-
Han, Yue, Wang, Jingyi, Zhang, Jin, Zheng, Xi, Jiang, Yijia, Liu, Wei, and Li, Wenxiong
- Subjects
PSEUDOMONAS aeruginosa infections ,ACUTE kidney failure ,MITOGEN-activated protein kinases ,BLOOD urea nitrogen ,EPITHELIAL cells - Abstract
Purpose: Sepsis-associated acute kidney injury (S-AKI) contributes to high mortality, but it is lack of specific treatments. We aimed to investigate the underlying mechanism of S-AKI and to identify target drugs to alleviate AKI. Methods: We establish a stable mouse model of S-AKI by Pseudomonas aeruginosa incision infection. Based on high-throughput sequencing and bioinformatics analysis, we investigated the underlying mechanism and selected the target drug (VX-702) for S-AKI. An in vitro model established by co-cultured of kidney tubular epithelial cell line (TCMK-1) cells with lipopolysaccharide (LPS)-induced leukemic monocyte/macrophage cells (RAW264.7), we explored the effect of VX-702 on S-AKI. Results: The data showed interleukin (IL)-6 and IL-1β were the hub genes, and the mitogen-activated protein kinase (MAPK) signaling pathway was the main pathway involved in S-AKI. Administration of VX-702 by oral gavage decreased the elevated concentrations of IL-6, IL-1β, serum creatinine, and blood urea nitrogen in mice with S-AKI. Moreover, VX-702 reduced the number of apoptotic cells in damaged kidney tissues. Cell viability was decreased, and the number of apoptotic cells was increased in TCMK-1 cells co-cultured with LPS-induced RAW264.7 cells compared to LPS-induced TCMK-1 cells. VX-702 treatment reversed this effect. VX-702 treatment reduced the levels of phosphorylated p38 MAPK and proinflammatory cytokines in RAW264.7 cells and the supernatant. VX-702 could bind IL-6, IL-1β and MAPK, and affect the binding of IL-1β and its receptor, as demonstrated by molecular docking. Conclusion: VX-702 ameliorated S-AKI by inhibiting the release of proinflammatory cytokines from macrophages, indicating its potential as a novel therapeutic for S-AKI treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Distribution of pathogenic variants in the CFTR gene in a representative cohort of people with cystic fibrosis in the Kingdom of Bahrain.
- Author
-
Majed, Osama A. Karim, Majed, Fatema Osama, Almoamen, Nabeel Jasim, Alsatrawi, Husain Baqer, Shehabi, Salma Dawood, Hrbková, Jana, Libik, Malgorzata, and Macek Jr., Milan
- Subjects
- *
CYSTIC fibrosis , *GENETIC variation , *SICKLE cell anemia , *NEWBORN screening , *CYSTIC fibrosis transmembrane conductance regulator , *PSEUDOMONAS aeruginosa infections - Abstract
Background: Cystic fibrosis (CF) is a rare multi-systemic recessive disorder. The spectrum and the frequencies of CFTR mutations causing CF vary amongst different populations in Europe and the Middle East. In this study, we characterised the distribution of CF-causing mutations (i.e. pathogenic variants in the CFTR gene) in a representative CF cohort from the Kingdom of Bahrain based on a three-decade-long analysis at a single tertiary centre. We aim to improve CF genetic diagnostics, introduce of CF neonatal screening and provide CFTR modulator therapy (CFTRm). Methods: CFTR genotyping and associated clinical information were drawn from a longitudinal cohort. We sequenced 56 people with CF (pwCF) that had one or both CFTR mutations unidentified and carried out comprehensive bioinformatic- and family-based segregation analyses of detected variants, including genotype–phenotype correlations and disease incidence estimates. The study methodology could serve as a basis for other non-European CF populations with a high degree of consanguinity. Results: Altogether 18 CF-causing mutations were identified, 15 of which were not previously detected in Bahrain, accounting for close to 100% of all population-specific alleles. The most common alleles comprise c.1911delG [2043delG; 22.8%], c.2988+1G > A [3120+1G>A; 16.3%], c.2989-1G>A [3121-1G>A; 14.1%], c.3909C>G [N1303K; 13.0%], and c.1521_1523delCTT [p.PheF508del; 7.6%]. Although the proportion of 1st cousin marriages has decreased to 50%, the frequency of homozygosity in our pwCF is 67.4%, thereby indicating that CF still occurs in large, often related, families. pwCF in Bahrain present with faltering growth, pancreatic insufficiency and classical sino-pulmonary manifestations. Interestingly, two pwCF also suffer from sickle cell disease. The estimated incidence of CF in Bahrain based on data from the last three decades is 1 in 9,880 live births. Conclusion: The most commonCF-causing mutations in Bahraini pwCF were identified, enabling more precise diagnosis, introduction of two-tier neonatal screening and fostering administration of CFTRm. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Benzyl isothiocyanate as an alternative to antibiotics? a comparative in vivo study using Pseudomonas aeruginosa infection as a model.
- Author
-
Yang, Jian, Hediyal, Tousif Ahmed, Chidambaram, Saravana Babu, Kaul-Ghanekar, Ruchika, and Sakharkar, Meena Kishore
- Subjects
- *
PSEUDOMONAS aeruginosa infections , *IN vivo studies , *ANTIBIOTICS , *PSEUDOMONAS aeruginosa , *ANTI-infective agents , *COMPARATIVE studies - Abstract
Due to over-prescription of antibiotics, antimicrobial resistance has emerged to be a critical concern globally. Many countries have tightened the control of antibiotic usage, which, in turn, promotes the search for alternatives to antibiotics. Quite a few phytochemicals have been investigated. Benzyl isothiocyanate (BITC) is an important secondary metabolite in cruciferous species and exhibited potent antimicrobial activity under in vitro conditions. In this research, we undertook a comparative mouse model study of BITC with gentamycin sulfate (positive antibiotic control) and ceftiofur hydrochloride (negative antibiotic control) against Pseudomonas aeruginosa infection. Our results showed that BITC exhibited comparable or better antimicrobial activity and lower infiltration of mouse immune cells upon comparing to gentamycin sulfate. Furthermore, BITC did not impose any toxicity to the air pouch skin tissues. In summary, our current study suggests that BITC could be an alternative to antibiotics and deserves further in vivo and clinical trial studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.